CJC-1295 and Ipamorelin: What High-Performing Adults Should Know Before Starting a Peptide Protocol
Most of the executives, founders, and physicians I see in our practice are not looking for a magic bullet. They want a considered plan, honest data, and someone who will tell them when a protocol is a bad fit. Growth hormone secretagogues like CJC-1295 and ipamorelin come up often in those conversations, usually because a friend mentioned them or a longevity podcast made them sound essential. Both things can be true: the science is interesting, and the marketing has run well ahead of it.
Here is what I want you to understand before you start.
What these peptides actually do
CJC-1295 and ipamorelin are two different molecules that work on two different receptors, which is precisely why they are typically prescribed together.
CJC-1295 is a growth hormone-releasing hormone (GHRH) analog. It signals the pituitary through the GHRH receptor to release growth hormone. The version most commonly used in a clinical setting is CJC-1295 without DAC, which has a short half-life measured in minutes and produces a pulse of GH release rather than a sustained elevation. The "with DAC" version binds to albumin and stays active for days, which sounds convenient but blunts the natural pulsatility that makes the endocrine system work properly. That pulsatility matters.
Ipamorelin is a ghrelin-receptor agonist, or a growth hormone-releasing peptide (GHRP). It works on a separate pathway to trigger GH release and, importantly, is more selective than older peptides in its class. It does not meaningfully raise cortisol or prolactin at typical doses, which is one reason it has become a preferred pairing.
When you combine a GHRH analog with a GHRP, you get a synergistic pulse of endogenous growth hormone that is larger than either alone. The key word is endogenous. You are not injecting growth hormone. You are asking your own pituitary to release more of it, within the feedback loops your body already runs.
Why high performers become interested
The patients who ask me about these protocols tend to describe a specific cluster of complaints. Sleep that used to be effortless now takes work. Recovery from a hard training session stretches from one day to three. Visceral fat accumulates despite unchanged habits. Skin quality changes. Injuries linger.
Growth hormone declines steadily from your late twenties onward, and IGF-1 follows. The reasonable clinical question is whether restoring a more youthful GH pulse pattern produces meaningful benefit for body composition, sleep architecture, and connective tissue repair. In the right patient, with the right baseline labs, we do see improvements in deep sleep, waist circumference, and subjective recovery. I want to be careful with that statement. These are protocols, not cures, and individual responses vary considerably.
Who is a reasonable candidate, and who is not
Before I write a prescription, I want to see a full workup. That includes IGF-1, a complete metabolic panel, fasting insulin, HbA1c, a thyroid panel, sex hormones, and often an inflammatory marker or two. If your IGF-1 is already in the upper quartile for your age, you probably do not need this. If your fasting insulin is high and you have not addressed metabolic health, adding a GH secretagogue is putting a nice hat on a house fire.
Contraindications I take seriously:
- Active malignancy or recent cancer history. GH and IGF-1 are trophic hormones, and we do not want to feed cells that should not be growing.
- Untreated diabetic retinopathy or poorly controlled type 2 diabetes. GH is counter-regulatory to insulin.
- Pregnancy or planning pregnancy.
- Severe untreated sleep apnea, which should be addressed first.
Age matters too. In our practice, most candidates are 35 and up, with declining IGF-1, real symptoms, and a metabolic picture clean enough to justify the intervention. A 32-year-old with excellent labs who wants to biohack rarely benefits enough to justify the cost and complexity.
What a protocol typically looks like
Dosing is individualized, but a common approach is a subcutaneous injection at night, five nights per week, with two off-nights to preserve receptor sensitivity. Nighttime dosing takes advantage of your body's largest natural GH pulse, which occurs during early slow-wave sleep. You inject on an empty stomach, since a rise in blood glucose or a large meal will blunt the GH response.
Cycle length varies. Some clinicians run continuous protocols with periodic breaks; others prefer three to six month cycles with washout periods. I lean toward the latter for most patients because it respects the feedback loops and gives us a clean opportunity to reassess labs and symptoms.
Expect to feel very little in the first two to four weeks. Sleep depth often changes first. Body composition shifts, if they occur, take two to three months to become visible. IGF-1 is the objective marker we track, and I want to see it move into the upper end of the age-appropriate range without exceeding it.
Side effects and honest caveats
The most common side effects are mild and dose-related: transient flushing, tingling in the hands, a hungry feeling shortly after injection (ipamorelin acts on the ghrelin receptor), and occasional injection-site redness. Water retention and mild joint aches can appear if IGF-1 climbs too quickly. These typically resolve with a dose adjustment.
The bigger caveats are structural. Long-term safety data in healthy adults are limited. We are extrapolating from shorter studies, from GH deficiency literature, and from clinical experience. Anyone who tells you these peptides are risk-free is not being straight with you. Anyone who tells you they will add a decade to your life is selling something.
Sourcing matters enormously. Peptides purchased from research chemical websites are not manufactured to pharmaceutical standards, are frequently mislabeled, and sometimes contain contaminants. A legitimate protocol comes from a licensed prescriber working with a compounding pharmacy that follows USP standards.
How to think about this in the context of your broader health
Peptides are a lever, not a foundation. In every patient I have seen respond well, the fundamentals were already in place: consistent sleep, resistance training, protein intake in the range of 0.8 to 1 gram per pound of lean mass, alcohol kept modest, and reasonable metabolic markers. When someone tries to use CJC-1295 and ipamorelin to compensate for four hours of sleep and a bottle of wine most nights, the results are predictably underwhelming.
I also think carefully about how these protocols fit alongside hormone optimization, Weight Management strategies, and, where relevant, Intimate Wellness concerns. These systems talk to each other. Testosterone influences GH sensitivity. Thyroid status affects IGF-1 conversion. Insulin resistance blunts everything. A good protocol is one piece of a coherent plan, not a standalone intervention.
Questions worth asking before you start
- What are my baseline IGF-1 and metabolic markers, and where should they be?
- Who is compounding the peptide, and can I see documentation?
- How will we measure response, and at what interval?
- What is the plan if IGF-1 rises too high, or if I develop side effects?
- How does this interact with the other things I am doing for my health?
If your prescriber cannot answer these clearly, find a different prescriber.
For patients who are appropriate candidates and who approach this thoughtfully, CJC-1295 and ipamorelin can be a useful tool. For patients who are not, they are an expensive distraction. The only way to know which group you are in is a real evaluation with someone who will tell you the truth. If you would like to explore whether a peptide protocol makes sense for you, request a consultation with our team and we will start with the labs and the conversation, not the prescription pad.
Peptide therapies discussed here are not FDA-approved and are offered pursuant to Fla. Stat. § 458.3245.
Related from Hew Health